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Objective: Despite a generally good prognosis, many prostate cancer survivors have poor
quality of life (QOL). A greater understanding of how psychological appraisals influence QOL is
merited given their potentially modifiable nature. In this study, we considered how elements of
survivors' retrospective and prospective appraisals relate to QOL.
Methods: A total of 1229 prostate cancer survivors between 2 and 5 years post‐diagnosis,
identified from a population‐based National Cancer Registry, were asked questions on their
socio‐demographics, health, treatment received, and adverse‐effects using a cross‐sectional
design. QOL was assessed using the EORTC QLQ‐C30. Retrospective appraisals were assessed
by asking survivors to reflect on their experience of treatment‐related adverse‐effects compared
with their prior expectations. A fear of recurrence scale assessed prospective appraisals of future
disease course. A multiple regression model explored the impact of psychological appraisals on
QOL, after controlling for socio‐demographic, treatment, and health‐related factors.
Results: The model was significant explaining 37% of variance in QOL. The strongest associ-
ate with QOL was fear of recurrence (β = −.29; P < .001). Survivors who experienced side effects
that were worse than expected had significantly lower QOL (β = −.10; P = .002). Other significant
correlates of lower QOL were presence of comorbidities, having undergone a less invasive
treatment, and having more advanced disease. Working at diagnosis and having a higher level
of education were significantly associated with higher QOL.
Conclusions: Results suggest both retrospective and prospective appraisals are indepen-
dently related to QOL in prostate cancer. Providing survivors with more information about
possible adverse effects of treatment, as well as providing appropriate information regarding
future disease progression, may improve QOL.
KEYWORDS
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appraisals, quality of life1 | INTRODUCTION
It is well established that a cancer diagnosis and its treatment can lead
to detriments in quality of life (QOL) among survivors.1 While survival
rates for prostate cancer are high and increasing,2 some survivors have
low QOL.3 This can, in part, be attributed to the numerous adverse‐
effects that often ensue following diagnosis and treatment, includingwileyonlinelibrary.com/joururinary incontinence, bowel problems, erectile dysfunction, and
fatigue.4 Such side effects can often be debilitating with potential to
cause considerable impact on survivors' daily lives and psychological
wellbeing.5-7
While clinical factors such as cancer stage, time since diagnosis,
comorbidities, and treatment are known to be associated with QOL
in cancer survivors,3,6,8 there is a growing recognition of the importantCopyright © 2018 John Wiley & Sons, Ltd.nal/pon 1237
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well‐being.9,10 For example, research has shown that a survivor's
expectations over future disease course, specifically their fears of
recurrence (FOR), can negatively impact QOL.11,12 FOR, which can
be viewed as a prospective appraisal, encapsulating survivors' fears
and uncertainty about future disease progression, is a common
concern among cancer survivors,12,13 including those with prostate
cancer.14-18 Such fears are likely to have an impact on QOL even in
the absence of a genuine clinical risk of recurrence.
Survivors also make retrospective appraisals of their illness and
treatment,19 and these too could influence wellbeing.20 In a recent
meta‐analysis,21 survivors' expectations of side effects, or Response
Expectancies, were found to be related to later experience post‐treat-
ment. In prostate cancer, many patients have unrealistic expectations
of side effects.22 Therefore, if survivors experience treatment‐related
side effects that they had not anticipated, or more specifically, that
were worse than expected, this may lead to regret over treatment
decisions and, hence, lower QOL.23 However, little research has inves-
tigated whether retrospective appraisals of this nature are associated
with QOL. Theories of expectation violation imply that the more dis-
crepant an individual's experience is with their prior expectations, the
greater the state of cognitive disequilibrium.24 However, it is unclear
whether expectation violations resulting in positive (ie, better than
expected) and negative (ie, worse than expected) outcomes would
have the same effect on QOL.
This paper aims to establish whether reflections on prior treat-
ment expectations (a retrospective appraisal) and FOR (a prospective
appraisal) are independently associated with QOL in prostate cancer
survivors, after controlling for known socio‐demographic, health, and
treatment‐related predictors of QOL. A greater understanding of both
retrospective and prospective appraisals is merited as this offers the
potential to inform interventions aimed at increasing QOL in addition
to interventions focusing on health status and the management of side
effects. We hypothesise that both appraisals will have an independent
relationship with QOL.2 | METHODS
2.1 | Ethical statement
Prior to gathering data, ethical approval was granted from the Irish
College of General Practitioners. Survivors were identified from the
National Cancer Registry, Ireland which contains information on all
those diagnosed with prostate cancer in the Republic of Ireland.
Exclusion criteria included being deceased, under the age of 18, less
than 2 years post‐diagnosis, suffering from any cognitive impairment,
or not being well enough to complete the questionnaire. Any men
deemed ineligible by health care professionals were also excluded.2.2 | Design and sample
This study was nested within the PiCTure project which investigated
the experiences and outcomes of prostate cancer survivors in Ireland.
The project's objective was to perform an international population‐
based Patient‐Reported Outcomes study relating to the diagnosisand treatment of prostate cancer.5,7,25 The hypotheses for the current
study fit with this objective. Following screening for eligibility by
general practitioners, 4453 survivors were invited to complete a
postal questionnaire between April and September 2012. Separate
questionnaires were developed for survivors between 2 and 5 years
post diagnosis and those greater than 5 years post‐diagnosis. Survivors
in the Republic of Ireland between 2 and 5 years post‐diagnosis were
asked to complete a FOR scale in addition to a core questionnaire
(see supplementary figure). It is these survivors who were focused on
in the current study. The 5‐year post diagnosis mark is a critical
milestone for survivors with the expectation of a lower risk of
recurrence at this stage.2.3 | Measures
2.3.1 | Quality of life
QOL was measured using the EORTC QLQC301 which has been used
in prostate cancer populations.5 This scale contains 30 items which
comprises 5 functional scales (physical, role, social, emotional, and cog-
nitive functioning), 9 symptom scales (fatigue, pain, nausea, dyspnoea,
insomnia, appetite loss, constipation, and financial difficulties), and an
overall global health score (GHS). With the exception of the GHS,
survivors are required to rate to what extent they have experienced
problems in the past week in each of the 14 domains on a scale of 1
(not at all) to 4 (very much). Following recent developmental work,26
we computed a summary QOL score by calculating the average of all
5 functional domains and 8 of the 9 symptom domains (financial
impact is not included in this computation, nor is the GHS). Scores
were then standardised to give an overall value of between 0 and
100 with higher scores indicating better QOL. This has been shown
to be a robust index of QOL, performing similarly, and in some cases
superiorly, to the original underlying QLQ‐C30 subscales.262.3.2 | Socio‐demographic and health information at
diagnosis
On the questionnaire, survivors provided information on their age,
marital status, employment status at diagnosis, and whether they
had, or had not experienced, any of a range of comorbidities at diagno-
sis (specifically, heart disease, lung disease, stroke, diabetes, depres-
sion, high blood pressure, diverticular disease, bowel problems, other
cancer, or any other health problems). Information on time since
diagnosis and stage at diagnosis was obtained from NCRI records.2.3.3 | Treatment, side effects, and retrospective
appraisals
Survivors were asked to indicate whether they had received any of the
following treatments for their cancer: radical prostatectomy (RP),
external beam radiotherapy (ERBT), brachytherapy (BT), and/or andro-
gen deprivation therapy (ADT). They were also asked if they had ever
undergone watchful waiting or active surveillance. Based on this infor-
mation and following Drummond et al,5 a single hierarchical variable
was created to encapsulate treatment invasiveness: RP, ERBT with
concurrent ADT, ERBT without concurrent ADT, brachytherapy, ADT
alone, and monitoring only (watchful waiting and/or surveillance).
TABLE 1 Descriptive statistics
Categorical Variables No. %
Marital status
Married/cohabiting 658 80.5%
Other 151 18.5%
Missing 8 1.0%
Total 817 100%
Education
Primary 225 27.5%
Secondary 342 41.9%
Third level 223 27.3%
Missing 27 3.3%
Total 817 100%
Employment status at diagnosis
Employed/
self‐employed
369 45.2%
Other 399 48.8%
Missing 49 6.0%
Total 817 100%
Disease extent at diagnosis
Stage 1/2 633 77.5%
Stage 3/4 144 17.6%
Missing 40 4.9%
Total 817 100%
Primary treatment(s)
RP 258 31.6%
ERBT with ADT 156 19.1%
ERBT without ADT 253 31.0%
BT 65 8.0%
ADT only 44 5.4%
Monitoring only 27 3.3%
Missing 14 1.7%
Total 817 100%
Expectations of side effects
Did not have
side effects
123 15.1%
Not as bad as expected 195 23.9%
Same as expected 243 29.7%
Worse than expected 200 24.5%
Missing 56 6.9%
Total 817 100%
Continuous
variables Mean SD Range
Possible
range
Survivor age 68.48 7.87 47‐91 18+
Time since diagnosis
(years)
3.41 1.13 2‐5 2‐5
Number of 0.87 0.949 0‐6 0+
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experiencing any of the following potential treatment‐related side
effects: urinary incontinence; bowel problems; gynecomastia; sweats;
hot flashes; fatigue; loss of sexual desire; and/or depression.4 This
enabled a total number of ongoing side effects to be computed ranging
from 0 to 8.
Another question required survivors to reflect on whether or not
their experience of side effects was in line with what they had
expected. Following Gray et al,27 they were asked to indicate whether
they (1) did not experience any side effects, or had side effects that
were (2) not as bad as expected, (3) the same as expected, or (4) worse
than expected. This was used as a measure of retrospective appraisals
of side effects with higher scores representing more negative viola-
tions of expectations.
2.3.4 | Prospective appraisals—fear of recurrence
FOR was measured using a 5‐item scale28 which has been previously
used in prostate cancer populations.14,16 This required survivors to
report their worries over cancer (eg, “I will probably relapse within
the next years,” “My fear of cancer getting worse gets in the way of
my enjoying life”) as well as 1 item relating to optimism over prognosis
(“I am certain that I have been cured of cancer”). Items are scored on a
5‐point Likert scale ranging from strongly agree to strongly disagree.
After recoding the optimism item, total values were summed and
standardised to provide an overall score from 0 to 100 with higher
scores corresponding to greater FOR. Reliability for this measure was
good with a Cronbach's alpha in our sample of 0.84.
2.3.5 | Statistical analysis
Variables were entered into a hierarchical multiple regression model
with 2 separate blocks. The first block included socio‐demographic,
treatment‐related, and health‐related information, specifically: current
survivor age, marital status, highest level of education completed,
employment status at diagnosis, number of comorbidities, time since
diagnosis, cancer stage, treatments received, and number of treat-
ment‐related side effects. The second block included the 2 psycholog-
ical appraisals, specifically prior expectations of side effects
(retrospective appraisal) and FOR (prospective appraisal). The criterion
variable was QOL as measured by the summary score from the
QLQC30. Descriptive statistics were calculated, and preliminary analy-
sis undertaken to ensure that no violations regarding assumptions of
normality, linearity, or homoscedasticity. Correlation analysis revealed
no notable multicollinearity between the predictor variables (see sup-
plementary table). All variables in the 2 blocks were included in the
model. Associations with QOL were assessed using 2‐sided t‐tests
and P values of <0.05 were considered significant.
comorbidities
Number of side
effects
2.16 1.72 0‐8 0‐8
FOR 29.42 20.97 0‐100 0‐100
QOL 86.56 14.35 12.39‐100 0‐100
Abbreviations: ADT, androgen deprivation therapy; BT, brachytherapy;
ERBT, external beam radiotherapy; RP, radical prostatectomy.3 | RESULTS
3.1 | Descriptive statistics
A total of 817 survivors were included in the analysis with those miss-
ing data excluded. Table 1 displays descriptive statistics for the sample.
The majority of survivors (81%) were married/cohabiting and had
1240 MAGUIRE ET AL.completed secondary education (42%). Just under half reported work-
ing at diagnosis. In terms of health status, 78% has stage I/II cancer.
The most common treatment type was RP (32%) followed by ERBT
without concurrent ADT (31%). The mean number of comorbidities
was 0.87, although 44% reported none. On average, respondents
reported having 2 ongoing treatment‐related side effects; 19% had
none. In terms of retrospective appraisals, 30% experienced side
effects the same as expected, 24% reported side effects were not as
bad as expected, and for 25% side effects were worse than expected.
While FOR was low on average, there was considerable variation, sug-
gesting that a sizeable minority experience considerable cancer‐related
worry with 19% having a FOR score above 50 (mean = 29.42; standard
deviation = 20.97). QOL was generally high with 86% of the sample
experiencing QOL scores in the top quartile (mean = 86.56; standard
deviation = 14.35).3.2 | Regression analysis
The results of the regression analysis are displayed in Table 2.
Sociodemographic, health, and treatment‐related factors (block 1)
explained 28% of the variance in QOL scores (P < 0.001). The psycho-
logical appraisals (block 2) explained a further 9% of variance in QOL
scores (P < .001). The model as a whole was significant (P < .001)
and explained 37% of variance in QOL.
Consistent with our hypotheses both FOR (β = −.29, P < .001) and
expectations of side effects (β = −.10, P = .002) were significant predic-
tors of QOL, after adjusting for other factors. FOR was the strongest
predictor of all the variables included in the model. Specifically, the
higher the survivors' FOR, and the worse their experience of side
effects compared with previous expectations, the lower their QOL.TABLE 2 Regression analyses for variables predicting QOL
Variables β p
Step 1: Sociodemographic, health, and treatment
Age .023 .54
Marital status [other = 0; married/cohabiting = 1] .044 .13
Education level [higher = higher level of education] .092** .00
Employment status [other = 0; employed = 1] .095** .00
Comorbidity [higher = more pre‐existing conditions] −.208*** .00
Time since diagnosis in years [higher = greater time] −.091** .00
Stage of cancer [stage 1/2 = 0; stage 3/4 = 1] −.071* .01
Primary treatment [higher = less invasive treatment] −.106** .00
Current side effects [higher = more side effects] −.267*** .00
R2 Change = 0.28
Step 2: Psychological appraisals
Expectations of side effects [higher = worse than
expected]
−.102** .00
Fear of recurrence [higher = greater fears] −.290*** .00
R2 Change = 0.09
R2 = 0.37
Statistical significance:
*P < .05.
**P < .01.
***P < .001.Additional significant predictors of higher QOL were having fewer
ongoing side effects (β = −.27, P < .001), having fewer comorbid condi-
tions (β = −.21, P < .001), having less invasive treatment (β = −.11,
P = .001), having earlier stage cancer (β = −.07, P = .02), and being a
shorter time since diagnosis (β = −.09, P = 006). Two sociodemographic
factors were significantly associated with higher QOL, specifically
having achieved a higher level of education (β = −.09, P = .002), and
working at the time of diagnosis (β = .10, P = .005).4 | DISCUSSION
The aim of this study was to investigate the association between
retrospective and prospective appraisals and QOL in prostate cancer
survivors. Both these appraisals were associated with survivor
well‐being and were evident after accounting for a range of
sociodemographic, health, and treatment‐related predictors of QOL.
This points to their importance and paves the way for interventions
with a view to increasing QOL.4.1 | The importance of appraisals and expectations
The finding that expectations regarding future disease course were
related to survivor QOL is in keeping with a number of studies which
have shown the important influence FOR has in determining QOL in
prostate cancer.14-17 We have shown that FOR acts independently
of clinical variables such as cancer stage, number of comorbidities,
treatment type, and side effects, in predicting QOL. The fact that
FOR emerged overall as the strongest correlate of well‐being clearly
illustrates the pertinent relationship between prospective illness
appraisals and well‐being.t B SE CI95%
0 .613 .046 .076 −.102 .195
5 1.497 1.875 1.252 −.584 4.333
2 3.087 1.820 .590 .663 2.978
5 2.803 3.012 1.075 .902 5.122
0 −6.851 −3.384 .494 −4.354 −2.414
6 −2.779 −.406 .146 −.692 −.119
8 −2.370 −2.763 1.166 −5.053 −.474
1 −3.253 −1.075 .331 −1.724 −.426
0 −8.168 −2.306 .282 −2.860 −1.751
2 −3.180 −1.564 .492 −2.530 −.598
0 −9.249 −.219 .024 −.265 −.172
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associated with survivors' retrospective appraisals of their prior treat-
ment expectations. Specifically, QOL was lower in survivors who
reported their side effects to be worse than previously expected. This
suggests that it is not only the severity or burden of side effects expe-
rienced which may influence QOL,4 but also how these experiences
are interpreted by survivors in light of previous expectations. This is
similar to our findings in relation to FOR, in that interpretations of risk,
rather than actual clinical risk of recurrence, may be a stronger
influence on QOL.
In keeping with these results, a number of longitudinal studies
have examined how prospective patient expectations are related to
later experience of side effects and QOL in cancer survivors. Often
referred to as response expectancies, these have been shown to have
associations with actual experience of side effects in that, when certain
side effects are expected, they are more likely to be later
reported.20,21,29,30 This has been termed the “nocebo” effect and is
considered a neurobiological problem influenced by the way in which
information is presented to patients.31 The nocebo effect has also
been demonstrated in prostate cancer32 where pre‐treatment expecta-
tions were associated with QOL following RP or radiotherapy.
Perhaps contrary to this research, our findings suggest that expec-
tations of more positive outcomes prior to treatment were negatively
associated with well‐being when these expectations did not match
actual experience. However, expectations were evaluated retrospec-
tively rather than prospectively which may explain this differing effect.
This finding fits with the wider literature on reasoning.24 More gener-
ally, this work suggests that when expectations are disconfirmed,
especially in light of negative outcomes, individuals may experience
surprise leading to a state of cognitive disequilibrium.33 Our findings
suggest that when survivors experience unanticipated adverse side
effects, this disequilibrium may lead to lower QOL, perhaps in a similar
way in which QOL may be impacted by FOR, given that this represents
perceived uncertainty over future disease course. On the other hand, it
is interesting to note that those survivors who had more positive expe-
riences than previously expected reported higher QOL. This suggests
that expectation violation per se does not lead to lower QOL, rather
it is how survivors interpret these expectation violations, either
positively or negatively, that is important.
While more than half of survivors in our sample reported
experiencing side effects that were either the same, or not as bad, as
expected, the fact that approximately 25% reported worse side effects
than expected suggests that a subset of survivors were not appropri-
ately prepared for the effects of treatment. This fits with research
reporting that prostate cancer patients can have unrealistic expecta-
tions regarding functioning after prostatectomy,22 although this may
vary depending on the particular side effects involved or treatment
undergone. For example, while only 22% experienced worse than
expected bowel and hormonal functioning following surgery, almost
half of patients experienced higher levels of urinary incontinence and
worse sexual function than expected.22 Our results highlight the
importance of acknowledging the role survivors' expectations have in
their well‐being. While providing patients with realistic expectations
regarding treatment is desirable, our findings suggest there may be
individual differences in the way survivors interpret these expectationsretrospectively. Health care professionals should thus be sensitive to
the way in which information on treatment and potential side effects
is presented to patients so that QOL can remain high after treatment
has ceased.
4.2 | Other predictors of QOL
Consistent with existing literature,34 it is not surprising to find that
other sociodemographic, health, and treatment‐related factors were
related to higher QOL, including higher education, being in employ-
ment at diagnosis, being diagnosed at an earlier stage of the disease,
and having fewer comorbid conditions. Interestingly, QOL decreased
between 2 and 5 years post diagnosis, highlighting the complex time
course of QOL in prostate cancer.35 This may be attributed to a greater
number of new comorbidities due to ageing, or more complex
psychological factors whereby men, once overcoming the initial shock
of diagnosis, realise that their level of functioning may not recover.
This fits with the finding that prostate cancer survivors have a lower
QOL than other cancer survivors 10 years post diagnosis, suggesting
that long‐term side effects can persist in this group.35 Furthermore,
we found survivors experiencing treatments such as ADT were more
likely to experience lower QOL highlighting the detrimental impact this
treatment can have on survivor well‐being.5 These findings add to
literature that highlights those most at risk of lower QOL in prostate
cancer. Furthermore, utilising the summary score of the QLQC3026
offers an alternative approach for measuring QOL that has not been
extensively adopted in this population.
4.3 | Study limitations
It is important to acknowledge the limitations of this study. Firstly,
given the cross‐sectional design, we cannot assume causality or indeed
the direction of the relationship between psychological appraisals and
QOL. It is possible for example that men who have lower QOL were
more likely to perceive their side effects to be worse than expected.
As previously mentioned, our measure of expectations was based only
on retrospective reflections rather than tracked longitudinally prior to
treatment. Also, we only examined 2 aspects of survivors' illness
appraisals. It is likely that other psychological appraisals of illness, both
prospective and retrospective, may influence well‐being. We also did
not take a measure of current comorbidities (beyond those at diagno-
sis) which may have influenced results. Finally, our study focused only
on survivors between 2 and 5 years post diagnosis so it is unclear how
appraisals may influence QOL in longer term survivors.
4.4 | Clinical implications
Given that FOR is a common concern in prostate cancer,17 in spite of
good prognosis following treatment, it is important health care profes-
sionals have a greater understanding of factors that put survivors most
at risk of lower well‐being. Our previous work in this study population
found that FOR is associated with type of treatment and regret over
treatment decisions.18 This suggests that simple measures, such as
providing survivors with more information surrounding treatment,36,37
may be beneficial in decreasing FOR. As suggested by our current
findings, such interventions might also yield benefits in terms of QOL.
1242 MAGUIRE ET AL.Consistent with recommendations,32 our findings highlight the
importance of ensuring patients have appropriate expectations regard-
ing QOL following treatment of prostate cancer. Health care profes-
sionals should be sensitive to the way in which information regarding
what to expect from treatment is presented to patients and, more
generally, should strive to support patients prior to, during, and after
treatment in order to facilitate positive appraisals throughout the
survivorship process.5 | CONCLUSIONS
Health care professionals now recognise the significant effect QOL has
on survivor prognosis and, as such, acknowledge the importance in
taking measures to improve this. Our study has shown that psycholog-
ical appraisals, both retrospective (in terms of mismatched side‐effect
expectations and experiences) and prospective (in terms of FOR), are
strongly related to QOL. This suggests that interventions focused on
alleviating fears and considering the most appropriate ways to present
information regarding potential side effects of treatment offer poten-
tial to improve well‐being among cancer survivors.
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